“Comparative analysis of the use of technetium-99m labeled recombinant target molecules at doses of 1000 and 2000 μg for radionuclide diagnostics of HER2-positive breast cancer”, Вопр. онкол., vol. 68, no. 1, pp. 60–65, Feb. 2022, doi: 10.37469/0507-3758-2022-68-1-60-65.